Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1984 May;51(5):539–544. doi: 10.1136/hrt.51.5.539

Development of congestive heart failure after treatment with metoprolol in acute myocardial infarction.

J Herlitz, A Hjalmarson, S Holmberg, K Swedberg, A Vedin, F Waagstein, A Waldenström, H Wedel, L Wilhelmsen, C Wilhelmsson
PMCID: PMC481545  PMID: 6372839

Abstract

In a double blind study of metoprolol in the treatment of suspected acute myocardial infarction 698 patients (study group) received metoprolol and 697 a placebo (control group). Metoprolol was given in an intravenous dose of 15 mg as soon as possible after admission to hospital followed by 50 g by mouth four times a day for two days and thereafter 100 mg twice a day for three months. A placebo was similarly given. Congestive heart failure occurred in a similar percentage of patients in both the study (27%) and the control groups (30%). Its severity was estimated by calculating the total dose of frusemide given during the first four days in hospital. Less frusemide was given to patients treated with metoprolol compared with those given a placebo in the total series. An appreciably lower total dose of frusemide was given to patients included in the trial less than or equal to 12 hours after the onset of pain and treated with metoprolol compared with a placebo, while no difference was seen among patients treated later. The initial heart rate, systolic blood pressure, and infarct site affected the results.

Full text

PDF
539

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Awan N. A., Miller R. R., Vera Z., Janzen D. A., Amsterdam E. A., Mason D. T. Noninvasive assessment of cardiac function and ventricular dyssynergy by precordial Q wave mapping in anterior myocardial infarction. Circulation. 1977 Jun;55(6):833–838. doi: 10.1161/01.cir.55.6.833. [DOI] [PubMed] [Google Scholar]
  2. Bleifeld W., Mathey D., Hanrath P., Buss H., Effert S. Infarct size estimated from serial serum creatine phosphokinase in relation to left ventricular hemodynamics. Circulation. 1977 Feb;55(2):303–311. doi: 10.1161/01.cir.55.2.303. [DOI] [PubMed] [Google Scholar]
  3. Brydon W. G., Smith A. F. An appraisal of routine methods for the determination of the anodal isoenzymes of lactate dehydrogenase. Clin Chim Acta. 1973 Feb 12;43(3):361–369. doi: 10.1016/0009-8981(73)90475-0. [DOI] [PubMed] [Google Scholar]
  4. Durrer J. D., Lie K. I., van Capelle F. J., Durrer D. Effect of sodium nitroprusside on mortality in acute myocardial infarction. N Engl J Med. 1982 May 13;306(19):1121–1128. doi: 10.1056/NEJM198205133061901. [DOI] [PubMed] [Google Scholar]
  5. Herlitz J., Elmfeldt D., Hjalmarson A., Holmberg S., Málek I., Nyberg G., Rydén L., Swedberg K., Vedin A., Waagstein F. Effect of metoprolol on indirect signs of the size and severity of acute myocardial infarction. Am J Cardiol. 1983 May 1;51(8):1282–1288. doi: 10.1016/0002-9149(83)90299-0. [DOI] [PubMed] [Google Scholar]
  6. Herlitz J., Waldenström J., Hjalmarson A. Relationship between the enzymatically estimated infarct size and clinical findings in acute myocardial infarction. Acta Med Scand. 1984;215(1):21–32. doi: 10.1111/j.0954-6820.1984.tb04965.x. [DOI] [PubMed] [Google Scholar]
  7. Hjalmarson A., Elmfeldt D., Herlitz J., Holmberg S., Málek I., Nyberg G., Rydén L., Swedberg K., Vedin A., Waagstein F. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981 Oct 17;2(8251):823–827. doi: 10.1016/s0140-6736(81)91101-6. [DOI] [PubMed] [Google Scholar]
  8. Jürgensen J. H., Frederiksen J., Hansen D. A., Pedersen-Bjergaard O. Limitation of myocardial infarct size in patients less than 66 years treated with alprenolol. Br Heart J. 1981 May;45(5):583–588. doi: 10.1136/hrt.45.5.583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kahn J. C., Gueret P., Baudet M., Rocha P., Bardet J., Bourdarias J. P. Clinical assessment of infarct size by serial determinations of serum creatine phosphokinase activity. Eur J Cardiol. 1979 Jan;9(1):21–37. [PubMed] [Google Scholar]
  10. Maroko P. R., Deboer L. W., Davis R. F. Infarct size reduction: A critical review. Adv Cardiol. 1980;27:127–169. doi: 10.1159/000383982. [DOI] [PubMed] [Google Scholar]
  11. Peter T., Norris R. M., Clarke E. D., Heng M. K., Singh B. N., Williams B., Howell D. R., Ambler P. K. Reduction of enzyme levels by propranolol after acute myocardial infarction. Circulation. 1978 Jun;57(6):1091–1095. doi: 10.1161/01.cir.57.6.1091. [DOI] [PubMed] [Google Scholar]
  12. Yusuf S., Ramsdale D., Peto R., Furse L., Bennett D., Bray C., Sleight P. Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. Lancet. 1980 Aug 9;2(8189):273–276. doi: 10.1016/s0140-6736(80)90231-7. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES